D
Autolus Therapeutics plc AUTL
$1.33 -$0.07-5.00% NASDAQ
Recommendation
Prev Close
$1.33
Volume
2,742,391
Avg Vol (90D)
1,544,428
Market Cap
$353.95M
Dividend & Yield
--
52-Week Range
$1.11 - $5.00
P/E (TTM)
--
EPS (TTM)
-$0.8684
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Q1 Earnings Estimate for AUTL Issued By William Blair
4/27/2025 - MarketBeat
Autolus Therapeutics (AUTL) Gains UK Approval for AUCATZYL in Leukemia Treatment AUTL Stock News
4/25/2025 - GuruFocus
Autolus Therapeutics (AUTL) Secures U.K. Approval for CAR-T Therapy Aucatzyl AUTL Stock News
4/25/2025 - GuruFocus
Autolus Therapeutics confirms license of Aucatzyl issued by U.K. MHRA
4/25/2025 - The Fly
Autolus Therapeutics' obecabtagene autoleucel conditionally approved by MHRA
4/25/2025 - The Fly
Autolus Therapeutics Announces License of AUCATZYL (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients ( 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
4/25/2025 - Globe Newswire
JPMorgan Chase & Co. Trims Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)
4/25/2025 - MarketBeat
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
4/23/2025 - Globe Newswire
Avoro Capital Advisors LLC Trims Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)
4/23/2025 - MarketBeat
Autolus Therapeutics to Present R&D Update April 23
4/23/2025 - TipRanks Financial Blog
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on ...
4/22/2025 - GuruFocus
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
4/22/2025 - Globe Newswire
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
4/16/2025 - Business Wire
Autolus Therapeutics' (AUTL) Buy Rating Reiterated at Needham & Company LLC
4/12/2025 - MarketBeat
HighPoint Advisor Group LLC Invests $185,000 in Autolus Therapeutics plc (NASDAQ:AUTL)
4/5/2025 - Ticker Report
Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12%
4/4/2025 - Simply Wall St
Truist Financial Lowers Autolus Therapeutics (NASDAQ:AUTL) Price Target to $10.00
4/2/2025 - MarketBeat
Autolus Therapeutics price target lowered to $10 from $11 at Truist
4/2/2025 - Yahoo! Finance: News
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
4/2/2025 - GuruFocus
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
4/2/2025 - Globe Newswire
Autolus Therapeutics price target lowered by $1 at Truist, here's why
4/1/2025 - The Fly
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
4/1/2025 - GuruFocus
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
4/1/2025 - Globe Newswire
Agilent Technologies (A): A Top Pick For The Best Retirement Portfolio
3/28/2025 - Insider Monkey
BIT Capital GmbH Buys 379,050 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)
3/28/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$10.12M
EBITDA (TTM)
-$233.07M
EBIT (TTM)
-$240.79M
Net Income (TTM)
-$220.66M
Balance Sheet
Total Assets (Q)
$782.73M
Total Debt (Q)
$297.23M
Total Liabilities (Q)
$355.40M
Book Value Per Share (Q)
$1.61
Cash Flow
Cash from Operations (TTM)
-$206.27M
Cash from Investing (TTM)
-$394.55M
Cash from Financing (TTM)
$589.55M
Net Change in Cash (TTM)
-$11.53M
Filings
Filing Date
Thursday, March 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.49
7-Day Total Return
-1.48%
30-Day Total Return
-28.88%
60-Day Total Return
-39.55%
90-Day Total Return
-46.59%
Year to Date Total Return
-49.43%
1-Year Total Return
-66.75%
2-Year Total Return
-18.90%
3-Year Total Return
-60.06%
5-Year Total Return
-86.69%
52-week Low
Apr 11, 2025 - $1.11
52-week High
Oct 18, 2024 - $5.00
Valuation
Market Cap
$353.95M - Small Cap
Enterprise Value
$63.16M
Price/Sales (TTM)
35.00
Price/Book (Q)
0.83
Dividends and Shares
Shares Outstanding
266.20M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.autolus.com
Phone Number
44 20 3829 6230
Address
The Mediaworks
191 Wood Lane - White City
London, W12 7FP
Country
United Kingdom
Year Founded
2014
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The... more
NASDAQ 04/25/2025 4:00PM Eastern Quotes delayed